CNS demyelination associated with nilotinib.
Saved in:
| Title: | CNS demyelination associated with nilotinib. |
|---|---|
| Authors: | Erturul, Ezgi (AUTHOR), Kocer, Belgin (AUTHOR), Gokce, Saliha (AUTHOR), Ucar, Murat (AUTHOR) |
| Source: | Neurological Sciences. Sep2023, Vol. 44 Issue 9, p3335-3339. 5p. 3 Black and White Photographs. |
| Subjects: | Nilotinib, Myelin sheath diseases, Demyelination, Platelet-derived growth factor receptors, Adult T-cell leukemia |
| Abstract: | Tumor necrosis factor-alpha inhibitors and immune-checkpoint inhibitors are the most frequently reported agents, but recently, the number of cases reporting iatrogenic central nerve demyelination with tyrosine kinase inhibitors has increased. Tumor necrosis factor-alpha inhibitors and immune-checkpoint inhibitors are the most frequently reported agents in iatrogenic central nervous system demyelination cases [[1]]. As treatment options for cancer and autoimmune diseases are developing each day, iatrogenic central demyelination case reports are increasing in number. [Extracted from the article] |
| Copyright of Neurological Sciences is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | Tumor necrosis factor-alpha inhibitors and immune-checkpoint inhibitors are the most frequently reported agents, but recently, the number of cases reporting iatrogenic central nerve demyelination with tyrosine kinase inhibitors has increased. Tumor necrosis factor-alpha inhibitors and immune-checkpoint inhibitors are the most frequently reported agents in iatrogenic central nervous system demyelination cases [[1]]. As treatment options for cancer and autoimmune diseases are developing each day, iatrogenic central demyelination case reports are increasing in number. [Extracted from the article] |
|---|---|
| ISSN: | 15901874 |
| DOI: | 10.1007/s10072-023-06827-4 |
